Table 1.
Patient characteristics
| Characteristic | TAC first (n=22) | LT first (n=27) | p-value |
|---|---|---|---|
|
Age, years, median (IQR)
Age at TAC Age at LT |
n=22 44.1 (38.3 – 49.1) 53.6 (45.9 – 57.6) |
n=27 51.0 (44.2 – 59.0) 43.5 (37.4 – 49.7) |
0.06 0.01 |
|
Sex, n (%)
Male Female |
n=22 17 (77.3) 5 (22.7) |
n=27 19 (70.4) 8 (29.6) |
0.75 |
|
Race, n (%)
White Black Asian |
n=22 18 (81.8) 4 (18.2) 0 (0.0) |
n=27 20 (76.9) 5 (19.2) 1 (3.8) |
0.74 |
|
IBD diagnosis, n (%)
Ulcerative colitis Crohn’s Indeterminant |
n=22 20 (90.9) 2 (9.1) 0 (0.0) |
n=25 23 (92.0) 1 (4.0) 1 (4.0) |
1.0 |
|
Indication for TAC, n (%)
Dysplasia Cancer |
n=22 11 (50.0) 11 (50.0) |
n=27 18 (66.7) 9 (33.3) |
0.26 |
|
Maintenance immunosuppression after LT, n (%)
Tacrolimus Tacrolimus and corticosteroids Tacrolimus, corticosteroids, and mycophenolate Tacrolimus and mycophenolate Cyclosporine, corticosteroids, and mycophenolate Tacrolimus, corticosteroids, and azathioprine Cyclosporine, corticosteroids, and sirolimus/everolimus |
n=25 9 (36.0) 6 (24.0) 5 (20.0) 2 (8.0) 1 (4.0) 1 (4.0) 1 (4.0) |